University of Bristol Selects Signant Health’s TrialConsent for Oncology Trial

October 14, 2019

Applied Clinical Trials

The National Institute for Health Research Bristol Biomedical Research Centre at the University of Bristol has selected Signant Health as its partner to provide electronic informed consent support for an oncology trial. The partnership will see Signant Health collect direct feedback from patients and sites on the impact of its TrialConsent platform during a prostate cancer study. The research seeks to understand how eConsent can improve patient comprehension and reduce site burden as well as to identify areas of opportunities and challenges for future clinical trials.

To get more information, click here.

Related Content:

News